The Role of the Small Bowel in the Regulation of Circulating Ghrelin Levels and Food Intake in the Obese Zucker Rat
http://www.100md.com
内分泌学杂志 2005年第4期
Institut de Recherche Contre les Canceurs de l’Appareil Digestif-European Institute of Telesurgery (F.R., A.F., M.V., J.M.), Université Louis Pasteur, 67091 Strasbourg, France; Institut National de la Santé et de la Recherche Médicale Unité 549 (P.Z., M.-T.B.-P., D.G.), 75014 Paris, France; Département de Pathologie Moléculaire (C.T.), Institut de Génétique et de Biologie Moléculaire et Cellulaire, Unité Propre de Recherche 6520 Centre National de la Recherche Scientifique/Unité 596 Institut National de la Santé et de la Recherche Médicale/Université Louis Pasteur, 67404 Illkirch, France; and Istituto di Clinica Chirurgica (F.R.), Catholic University, 00168 Rome, Italy
Address all correspondence and requests for reprints to: Francesco Rubino, M.D., Institut de Recherche Contre les Canceurs de l’Appareil Digestif-European Institute of Telesurgery, 1 Place de l’Hopital, 67091 Strasbourg, France. E-mail: f.rubino@lycos.com.
Abstract
Circulating levels of ghrelin, a stomach peptide that promotes food intake, rise before and fall after meal. We aimed to investigate whether there is an independent contribution of the small bowel to the regulation of ghrelin and appetite. A duodenal-jejunal bypass (DJB) with preservation of normal gastric volume and exposure to nutrients was performed in 12-wk-old obese Zucker ZDF fa/fa rat. Food intake, weight gain, 48-h fasting, and 24-h refeeding levels of total and acylated ghrelin were measured. The DJB was challenged against gastric banding (GB), diet, and a sham operation in matched animals. Normal controls were age-matched Wistar rats, which underwent either DJB or a sham operation. The Zucker obese animals showed a paradoxical increase of acylated ghrelin levels after refeeding (+30% with respect to fasting levels; P = 0.001), an abnormality that was completely reversed only by the DJB (–30%; P = 0.01) but not after GB, diet, or sham operation. In obese rats, the DJB resulted in significantly less food intake and weight gain compared with both GB (P < 0.05) and sham operation (P < 0.01). In sharp contrast, the DJB did not alter food intake and weight gain in normal rats. The DJB does not physically restrict the flow of food but restores meal-induced suppression of acylated ghrelin and significantly reduces food intake in Zucker obese rats. These findings suggest an independent intestinal contribution to the regulation of the dynamic ghrelin response to eating and the possibility that defective signaling from the proximal bowel could be involved in the pathogenesis of obesity/hyperphagia.
Introduction
OBESITY IS CONSIDERED the disease of the 21st century (1). At present, only bariatric surgery achieves major long-term weight loss (2, 3), possibly by counteracting the compensatory mechanisms that usually undermine the efficacy of nonsurgical strategies.
The Roux-en-Y gastric bypass (RYGB), which is one of the most effective and commonly performed procedures (4), includes reduction of gastric capacity to about 5% of its normal volume and a bypass of 95% of the stomach, the entire duodenum, and part of the jejunum (5, 6). In contrast to pure restrictive operations such as the adjustable gastric banding (AGB) and vertical banded gastroplasty, which simply induce early satiety during a meal (7), the RYGB reduces the number of meals and snacks per day and restricts consumption of calorie-dense foods (7, 8, 9, 10). Hence, satiety after RYGB extends well beyond the immediate postprandial period and therefore cannot be explained by gastric restriction alone. Understanding how RYGB prevents compensatory hunger after surgical weight loss may facilitate the development of new antiobesity drugs and perhaps shed light on the pathophysiology of obesity, which still remains elusive.
In 2002, Cummings et al. (11) found remarkably low plasma levels of ghrelin, a circulating orexigen (appetite stimulant), in patients who had undergone weight loss by RYGB, a finding that is in striking contrast with the fact that weight loss induced by dieting, anorexia, or regular physical exercise characteristically results in high levels of circulating ghrelin (11, 12). These authors suggested that ghrelin suppression might explain the loss of hunger after RYGB and possibly contributes to surgically induced weight loss (11). However, the issue is still controversial, as other series reported in the literature showed unchanged or even increased levels of circulating ghrelin in patients undergoing RYGB (13).
Ghrelin is a peptide hormone whose plasma levels increase before meals and decrease after food intake in humans and rodents (14, 15, 16). Because ingested nutrients are dominant regulators of ghrelin production (7, 12, 17) and the majority of ghrelin-producing tissue is located in the proximal stomach (18, 19), it has been hypothesized that RYGB disrupts ghrelin regulation by permanently excluding the fundus from contact with nutrients (7, 11, 20). Accordingly, differences in surgical technique, such as leaving behind a larger gastric pouch and an incomplete exclusion of the fundic part of the stomach from contact with the nutrient load, might explain why RYGB fails to suppress circulating ghrelin levels in some instances (12).
Although this is a plausible hypothesis, it is also entirely possible that changes in circulating ghrelin are the result of signals originating further downstream the gastrointestinal tract, away from the stomach, possibly as the result of the rerouting of food through the bowel according to the RYGB.
To test the hypothesis that intestinal signals are involved in the regulation of ghrelin production, we used a modified RYGB, which leaves the stomach intact and diverts food from the pyloric area directly to the distal jejunum (Fig. 1A). With this duodenal-jejunal bypass (DJB), the entire gastric ghrelin-producing tissue is left in digestive continuity, that is, in contact with nutrients. The operation does not involve any type of vagotomy, which could also influence ghrelin secretion (21, 22). Consequently, any change in circulating ghrelin levels occurring after DJB would be secondary to postgastric signals. Because this model does not impose any mechanical restriction on the flow of food, we also aimed to investigate whether the proximal bowel bypass may per se contribute to the control of appetite and weight loss.
FIG. 1. Surgical operations. A, DJB. The operation excludes the duodenum and jejunum from the flow of food. The length of the bypassed bowel is approximately the same as in standard RYGB in humans, but the DJB does not include bypass or restriction of the stomach. B, The GB operation provides a model of pure gastric restriction by inducing significant mechanical narrowing of the rat’s stomach. A nonresorbable inextensible band was placed just below the gastroesophageal junction calibrated to a standard length to provide a similar degree of gastric restriction in all animals.
Materials and Methods
Animals and chow diet
Male Zucker ZDF fa/fa rats aged 10 wk were purchased from Charles River Laboratories (l’Arbresle, France). Zucker ZDF rats are a widely used animal model of obesity and type 2 diabetes; they are characterized by leptin resistance, insulin resistance, and hyperphagia (22). Normal control animals were age-matched Wistar rats. Both obese animals and normal controls were housed under constant ambient temperature and humidity and in a 12-h light, 12-h dark cycle. All animals had free access to tap water and were ad libitum fed with Purina diet 5008 (IPS LTD, London, UK). The study was approved by the Institutional Animal Care Committee of the Institut de Recherche Contre les Canceurs de l’Appareil Digestif-European Institute of Telesurgery (Strasbourg, France).
Interventions
Zucker ZDF rats underwent one of DJB, GB, and sham operations. Normal controls underwent either DJB or the sham operation. An additional group of age-matched Zucker rats underwent food restriction to provide a model of diet-induced weight loss.
For all surgical procedures, 12-wk-old rats were fasted overnight and anesthetized with 2% isoflurane and air/oxygen.
DJB.
The volume of the stomach was left unperturbed, whereas the entire duodenum and the proximal jejunum were bypassed. This operation is a stomach-sparing bypass that excludes approximately the same amount of foregut excluded in standard RYGB in humans. The length of the bypass was made proportional to human RYGB by measuring the average length of rat intestine, which is approximately 95–100 cm long. The duodenum was separated from the stomach, and the bowel continuity was interrupted at the level of the distal jejunum (10 cm from the ligament of Treitz); the distal of the two limbs was directly connected to the stomach (gastrojejunal anastomosis); the proximal limb carrying the biliopancreatic juices was reconnected downward to the ileum at a distance of 15 cm from the gastrojejunal anastomosis (Roux-en-Y reconstruction). The procedure is illustrated in Fig. 1A.
GB.
The proximal stomach was exposed, and a nonresorbable 4-mm-wide band made of polytetrafluoroethylene (BardPTFE Braided Tape; Bard, Tempe, AZ) was placed just below the gastroesophageal junction, in a similar fashion to that usually performed during AGB in humans (23). The band was calibrated to a standard length to provide a similar degree of gastric restriction in all animals undergoing this operation. In addition, the band was fixed to the gastric wall by several nonresorbable stitches (3/0 nylon) to avoid slippage or band migration. The appropriateness of band position and calibration was checked at the time of death to exclude displacement of the band, which would influence results. Although this annular banding is not adjustable as is the AGB, it provides significant mechanical narrowing of the rat’s stomach, thus imposing restriction on the flow of food. The operation is illustrated in Fig. 1B.
Sham operation.
A gastrotomy was performed at the level of the gastric antrum and closed with an absorbable suture. Furthermore, transections and reanastomosis of the gastrointestinal tract were performed at the level of the duodenum and distal jejunum. The physiological flow of food through the bowel was left intact.
Food intake restriction.
After measuring the mean daily food intake for 2 wk in an age-matched and ad libitum-fed group of rats, access to food was then restricted to only one third of it for 4 consecutive weeks.
Weight change and food intake monitoring
Weight and food intake were measured daily for the duration of the study.
Sampling for plasma hormone measurements
From the tail of conscious rats, blood was collected in EDTA tubes containing the gastrointestinal preservative Aprotinin. After centrifugation at 3000 rpm and 4 C for 12 min, plasma was immediately separated and stored at –80 C until analysis.
Plasma glucose and hormone measurements (Fig. 2)
All blood sampling tests were performed between 0900 and 1100 h.
FIG. 2. Study’s protocol. The figure illustrates the timing of surgeries and testings.
Plasma hormone and glucose levels were measured in both positive and negative energy balance. To induce a negative energy balance, rats were deprived of food but not of water for 48 h before the experiment (48-h fasting). Then, blood samples were obtained again after a 24-h period of refeeding (RF) started at the time the rats had completed the 48-h fasting tests.
Postoperative 48-h fasting and RF tests were performed 3 wk after the operations.
Ghrelin.
Plasma levels of total and acylated ghrelin were determined by two laboratory immunoenzymatic assays using polyclonal rabbit antibodies against the C terminus of rat ghrelin (developed at the Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, France) and N-terminal rat ghrelin (kindly provided by Dr. Hosoda, Osaka, Japan), respectively, and human ghrelin was coupled to acetylcholinesterase (Spibio, Saclay, France) as tracer. The sensitivity was 100 and 20 pg/ml and the intra- and interassay coefficients of variation were 4 and 15%, respectively.
Leptin and insulin.
Plasma leptin and insulin concentrations were determined with RIA kits (Linco Research, St. Charles, MO). The sensitivity was 1 and 0.2 ng/ml, respectively, and the intra- and interassay coefficients of variation were less than 10% (intraassay, 2–4.6 and 1.4–4.6%; interassay, 3–5.7 and 8.5–9.4%, respectively).
Glycemia.
Plasma glucose levels were measured by enzymatic test (glucose oxydase; Beckman analyzer II; Beckman Coulter, Fullerton, CA).
Isolation of RNA and Northern hybridization
A portion of mucosa from the gastric body from each operated rat was taken at the time of and 4 wk after surgery. Surgical biopsies were rapidly frozen in liquid nitrogen. Total RNAs were extracted by the rapid guanidinium isothiocyanate procedure (43). The total RNA was fractionated by electrophoresis on 1% agarose, 2.2 M formaldehyde gels, transferred to nylon membrane (Hybond N; Amersham Corp. Arlington Heights, IL), and immobilized by baking for 2 h at 80 C. RNA loading was visualized by methylene blue staining. Membranes were hybridized at 42 C in 50% formamide, 5x standard saline citrate, 0.4% ficoll, 0.4% polyvinylpyrrolidone, 20 mM sodium phosphate (pH 6.5), 0.5% sodium dodecyl sulfate, 10% dextran sulfate, and 100 μg/ml denatured salmon sperm DNA, for 36–48 h, with the 32P-labeled specific rat ghrelin probe (GenBank accession no. AB029433) diluted to 0.5–1.106 cpm/ml. Stringent washings were performed at 60 C in 0.1x standard saline citrate and 0.1% sodium dodecyl sulfate. Filters were autoradiographed at –80 C for 12–72 h. The effect of different gastric surgeries on the expression level of ghrelin transcripts in the stomach was measured by Northern blot analysis.
Statistical analysis
Results are expressed as mean ± SEM. The changes in food intake, body weight, and plasma ghrelin levels were compared by ANOVA followed by Student’s t test. Comparisons between groups were performed with the unpaired t test. Simple linear regression analysis was used to evaluate correlation between body weight and plasma ghrelin levels. P < 0.05 was considered statistically significant.
Results
Effect of DJB on food intake and weight gain (Table 1)
To investigate the effect of the bypass of the foregut on appetite and body weight regulation, we compared food intake and percentage of weight gain in the different groups of rats for a period of 4 wk after surgery.
TABLE 1. Food intake and weight gain
In obese ZDF rats, the pure mechanical restriction induced by annular GB reduced food intake compared with sham-operated animals (mean daily food intake was 25.1 ± 1.2 vs. 30.8 ± 1.2 g/rat, respectively; P < 0.05; Fig. 3A). However, the most dramatic effect on food intake was seen in DJB-treated obese Zucker rats, which, despite the intact gastric reservoir, showed a lower daily rate of food intake (19.6 + 1.4 g/rat) than both GB and sham animals (P < 0.001) (Fig. 3A). In sharp contrast, DJB did not influence food intake in age-matched Wistar rats as demonstrated by identical average daily rates of food intake between DJB and sham-operated animals during the 4 wk of follow-up (Fig. 3A).
FIG. 3. Food intake and weight gain. A, Effect of DJB on food intake in lean (Wistar) and obese (Zucker) animals. DJB-treated Zucker rats ate significantly less food than GB-treated animals (P < 0.05) and sham-operated controls (P < 0.001). In contrast, DJB did not have any impact on food intake in Wistar rats, as shown by the fact that DJB-treated rats ate the same amount of food per day compared with sham-operated controls. Food intake is expressed as average daily food intake during the 4 wk of follow-up (grams per rat per day). B, Effect of DJB on weight gain in lean (Wistar) and obese (Zucker) animals. In Zucker rats, the DJB resulted in significant less weight gain compared with both GB (P < 0.05) and sham (P < 0.01) operations. In striking contrast, lean animals (Wistar) undergoing DJB showed the same weight gain as sham-operated rats. Weight gain is calculated as the percentage of body weight gained from the day of the operation.
In Zucker rats, the DJB resulted in significantly less weight gain compared with both GB and sham operations (P < 0.01; Fig. 3B). In striking contrast, DJB had no effect on control Wistar rats because they showed the same weight gain after DJB or sham surgery (Fig. 3B).
Zucker rats undergoing marked food restriction achieved a decrease in weight gain that was comparable with that of DJB [6.6 ± 0.6 vs. 5.2 ± 5.3%, respectively; P = not significant (NS)]. Hence, this group of rats was an appropriate control for comparing the hormonal effect of diet-induced weight loss vs. surgically induced weight loss.
Ghrelin mRNA expression
To assess for the integrity of ghrelin-secreting tissue in all rats undergoing surgery, we measured ghrelin mRNA in stomach biopsies obtained at the time of the operation and then again 4 wk after surgery. To ensure that biopsies of gastric mucosa were obtained from the same site at both times, the place of the first biopsy was marked by a stitch of nonresorbable suture.
No change in ghrelin mRNA expression could be detected after any type of surgery in ZDF rats (Fig. 4), demonstrating that all the different gastric surgeries performed in this study preserved the integrity of ghrelin-secreting gastric tissue, without apparent modification of ghrelin gene transcription.
FIG. 4. Expression of ghrelin transcripts by Northern blot analysis of rat’s gastric mucosa. The Northern blot contained approximately 10 μg total RNAs isolated from a nonoperated control rat (lane 1), sham-operated rats (lanes 2 and 3), GB-operated rats (lanes 4 and 5), and DJB-treated rats (lanes 6 and 7). The blot was hybridized using the homologous ppghrelin rat cDNA as a probe. Loading was visualized by the ribosomal 18S staining using methylene blue. RNA sizes are indicated on the left (kilobase pair values).
The effect of energy balance status on circulating ghrelin in obese and normal rats
To investigate ghrelin regulation in normal and obese rats, the effect of negative energy balance (48-h fasting) and positive energy balance (24-h RF) was tested in a group of 12-wk-old nonoperated ZDF rats (16 animals) and in 12-wk-old Wistar rats used as normal controls (16 animals).
Plasma total ghrelin levels were negatively correlated with body weight (r = –0.69, P < 0.001) and were significantly decreased by RF in each type of animals (lean and obese) (Table 2). However, mean ghrelin concentrations per gram of body weight were higher in obese Zucker rats than in normal Wistar rats (10.4 vs. 7.9 pg/ml·g body weight; P < 0.05), consistent with previous reports indicating that the obese Zucker rat is characterized by increased ghrelin mRNA in the stomach and peptide release in the circulation (24).
TABLE 2. Plasma glucose and hormones (nonoperated animals)
Although RF slightly reduced acylated ghrelin levels in normal control Wistar rats, the obese Zucker rats showed a paradoxical increase of acylated ghrelin levels after RF (+30% with respect to fasting levels; P = 0.002; Fig. 5).
FIG. 5. Ghrelin, leptin, insulin, and glycemia. Left, Total ghrelin levels decrease with RF in normal and obese animals. DJB-treated obese ZDF rats showed feeding-induced suppression of acylated ghrelin (–30% with respect to fasting; *, P = 0.01), whereas sham-operated ZDF rats maintained the paradoxical increase of acylated ghrelin with feeding. Right, Zucker ZDF rats are leptin resistant and show higher plasma leptin levels compared with Wistar rat. In Wistar rats, RF significantly increased leptin levels. In Zucker ZDF rats, there were no significant differences in leptin levels between the fasted and fed states; however, unlike sham-operated animals, the DJB-treated rats showed a trend toward increased levels of leptin with RF. Zucker ZDF rats had higher insulin levels than normal Wistar rats in both fasting and fed conditions. DJB-treated ZDF rats had lower levels of insulin compared with sham-operated animals; however, this difference does not reach statistical significance when considering the insulin to body weight ratio. Zucker ZDF rats have type 2 diabetes. Zucker DJB-treated animals had lower plasma glucose levels compared with sham-operated rats, especially in the fed condition. Remarkably, plasma glucose levels of Zucker rats treated by DJB were comparable with those of nondiabetic animals (Wistar rats). W, Wistar; ZDF, Zucker obese diabetic rats; *, P < 0.05; **, P < 0.01; **, P < 0.001.
The effect of surgery on circulating ghrelin levels
To investigate the possible role of the bowel in ghrelin regulation, the effect of DJB on total and acylated ghrelin in both fasted and fed states was compared with that of other gastric surgeries.
The experiments showed that DJB does not suppress circulating ghrelin levels in both normal and obese animals. Indeed, in fasting conditions, the Zucker rats that had undergone the DJB showed higher concentration of total and acylated ghrelin compared with sham-operated controls and GB rats as expected for their lower mean body weight. In normal Wistar animals, DJB did not have any impact on ghrelin response to eating. In contrast, DJB restored feeding-induced suppression of acylated ghrelin in the obese Zucker rats (–30% with respect to fasting; P = 0.01; Fig. 5), whereas neither the GB nor the sham operation caused significant change in the response of acylated ghrelin to food intake in these animals.
To investigate whether the effect of DJB on the ghrelin response to feeding was a specific outcome of the bypass of the proximal bowel and not secondary to the reduction of weight gain induced by the procedure, we tested the effect of diet-induced weight loss on circulating ghrelin in a group of matched Zucker rats undergoing food restriction for 4 wk. Despite a similar degree of weight gain compared with DJB rats, the diet group maintained the paradoxical increase of acylated ghrelin in response to feeding (330 ± 9 vs. 218 ± 23 pg/ml; P < 0.01).
The effect of surgery on leptin and insulin (Table 2 and Fig. 5)
To evaluate the effect of DJB on the secretion of long-term satiety hormones, we measured leptin and insulin levels in fasted and fed condition. Plasma leptin levels were significantly higher in obese Zucker rats compared with normal Wistar animals in both fasted and fed conditions.
The obese Zucker rats who had undergone DJB had significantly lower levels of plasma leptin compared with sham-operated animals and nonoperated controls; however, this difference disappears when considering the ratio of leptin to body weight (0.062 ± 0.003 vs. 0.066 ± 0.003 vs. 0.062 + 0.007 ng/ml·g body weight, respectively; P = NS). Furthermore, there was no difference in leptin levels in these rats after DJB- or diet-induced weight loss, suggesting that there was no direct impact of DJB on leptin secretion.
As expected, ZDF rats had higher plasma insulin levels than normal Wistar animals in both fasting and fed conditions (Fig. 5). Furthermore, in both obese animals and normal controls, RF after 48 h fasting significantly increased plasma insulin levels. DJB-treated ZDF rats had lower levels of insulin compared with sham-operated animals; however, this difference does not reach statistical significance when considering the insulin to body weight ratio.
The effect of DJB on type 2 diabetes
To investigate the effect of DJB on type 2 diabetes in the Zucker ZDF obese diabetic model, we tested plasma glucose in the fasted and fed states. The diabetic rats that had undergone DJB showed plasma glucose levels comparable with nondiabetic controls in both fasted and fed conditions. Sham-operated ZDF animals instead showed significantly higher glycemia, particularly in the fed state (Fig. 5).
Discussion
Ghrelin is a 28-amino-acid residue peptide predominantly produced by enteroendocrine cells in the oxyntic mucosa of the stomach (18, 19, 26). The acylation of one of its serine residues seems to have importance for its endocrine actions (27, 28), but the unacylated form has also been shown to possess metabolic effects (29). In both humans and rodents, ghrelin levels are increased by food deprivation and are decreased postprandially (14, 15, 16). However, how ingested nutrients interact with the ghrelin-producing cells is unclear.
Consistently with previous reports (30), this study found that, in obese Zucker rats, RF is associated with a paradoxical 30% increase of acylated ghrelin levels over fasting concentrations, suggesting that these obese animals are resistant to the meal-induced decrease of circulating acylated ghrelin. English et al. (31) reported that food intake fails to suppress plasma ghrelin levels also in obese humans. This altered endocrine response to eating in obese subjects may contribute to overeating and have implications for antiobesity therapies. Indeed, interventions in the dynamic response of ghrelin to eating, which seems to be altered in rodent and human obese subjects, may be a more effective way to fight obesity.
It has been suggested that RYGB may induce satiety and weight loss through suppression of circulating ghrelin levels (11) and that the mechanism responsible for the effect on ghrelin is the exclusion of the fundus and the isolation of ghrelin-producing cells from direct contact with ingested nutrients (11, 12, 20). However, this explanation is counterintuitive because an empty stomach is usually associated with increased ghrelin levels. We speculated that the rerouting of food through the bowel characteristic of the RYGB may influence ghrelin and appetite independently on fundus exclusion. The rationale for this hypothesis is that ghrelin-secreting cells in the stomach exist in both open and closed types (33), suggesting that they can receive both luminal and neuroendocrine information. Furthermore, recently published experiments put forward the possibility of a postgastric regulation of ghrelin secretion (34).
Unlike the standard RYGB, the DJB that we used in this study is an ideal model to test the hypothesis of an independent intestinal contribution to the regulation of circulating ghrelin levels because it allows one to rule out that any change in ghrelin and/or appetite is related to gastric exclusion/restriction.
Consistent with earlier reports showing no suppression in basal ghrelin levels in humans after RYGB (13), we did not observe suppression of mean total ghrelin levels after DJB. However, in obese Zucker rats, the operation reversed the altered response of circulating acylated ghrelin to feeding. The specificity of this result is demonstrated by the lack of such an effect in GB-treated and sham-operated Zucker rats as well as in the group undergoing diet. These findings support the hypothesis that intestinal signals contribute to the regulation (or dysregulation) of ghrelin secretion. It is possible that DJB influences ghrelin regulation by causing variations in gut hormone peptide YY (PYY) secretion, but other factors may also play a role (i.e. unknown peptides or neural signals from the bowel). Further exploration is necessary to understand how exactly the bowel influences ghrelin regulation.
The effect of DJB on appetite was also noteworthy. In this study, DJB decreased food intake in obese Zucker rats even more than GB, which is a pure restrictive procedure. The theoretical possibility that this effect could be determined by stenosis at the level of the gastrointestinal anastomosis is discounted by the fact that DJB-treated Wistar rats showed the same food intake rates compared with sham-operated controls. Furthermore, obese Zucker rats undergoing DJB still showed the ability to slightly increase their mean daily food intake with growth, a possibility that would be negated by the presence of significant stenosis.
The decreased food intake after the DJB may depend on the increase or enhancement of a factor inducing satiety and/or the reduction or inhibition of an antisatiety signal.
The lack of effect of DJB on food intake in normal Wistar rats, in sharp contrast with what is seen in obese animals, suggests that the second hypothesis is more likely. Previous work from our group showed that DJB does not reduce food intake in Goto-Kakizaki diabetic rats (35), which, like the Wistar rats used in the present study, are nonobese. Altogether, these observations suggest that the DJB may offset an abnormal signal produced by the bowel of hyperphagic/obese animals but not by the intestine of normal and lean rats. This implies the possibility that the gut plays an important role in the pathophysiology of hyperphagia and obesity. We speculate that failure to suppress an orexigenic signal originating in the bowel could result in persistence of the drive to eat even in the setting of positive energy balance, leading to excess energy storage and obesity. Our experiments and the clinical evidence that the most effective surgical operations in maintaining long-term weight loss are those that include a bypass of the foregut (biliopancreatic diversion and RYGB) (36) support the view of obesity as a disease of the bowel.
In this study, the DJB greatly reduced plasma glucose levels in obese diabetic Zucker rats, consistent with the knowledge that RYGB induces remission of type 2 diabetes in the majority of morbidly obese humans (37, 38). A recent study by two of us (F.R. and J.M.) demonstrated that this surgical control of diabetes depends on the bypass of the duodenal-jejunal tract, as shown by the fact that DJB (the same model used in the present study) controls type 2 diabetes in nonobese diabetic rats (Goto-Kakizaki rats), independently of caloric intake and weight loss (35).
Finally, our findings challenge the opinion that RYGB is primarily a restrictive operation (39, 40) and support an endocrine mechanism of action of the procedure (7, 41). Although it is generally believed that the small size of the gastric pouch is essential to reduce caloric intake and guarantee the weight loss effect of RYGB (39, 40, 42), our study suggests that performing an extremely small gastric pouch might be unnecessary. Certainly, a better understanding of the mechanism of action of RYGB is a priority because it may improve the design of bariatric operations.
In summary, our experiments demonstrate that the DJB, an experimental model of proximal bowel bypass with full preservation of the stomach, restores meal-induced suppression of acylated ghrelin and reduces food intake and weight gain in obese Zucker rats. Intriguingly, the operation does not alter food intake in normal Wistar animals. Altogether, these results indicate an intestinal contribution to the regulation of the dynamic ghrelin response to eating and suggest that an abnormal signaling from the proximal bowel may be involved in the pathogenesis of hyperphagia and obesity. Our experimental model, the DJB, may be useful to investigate intestinal factors regulating ghrelin secretion and appetite in the attempt to identify new targets for the development of antiobesity drugs.
Acknowledgments
The authors thank C. Wendling for technical assistance.
References
Kopelman PG 2000 Obesity as a medical problem. Nature 404:635–643
Brolin RE 2002 Bariatric surgery and long-term control of morbid obesity. JAMA 288:2793–2796
Mun EC, Blackburn GL, Matthews JB 2001 Current status of medical and surgical therapy for obesity. Gastroenterology 120:669–681
NIH Consensus Development Panel 1991 Gastrointestinal surgery for severe obesity. Ann Intern Med 115:956–961
Schauer PR, Ikramuddin S 2001 Laparoscopic surgery for morbid obesity. Surg Clin North Am 81:1145–1179
Jacob BP, Gagner M 2003 New developments in gastric bypass procedures and physiological mechanisms. Surg Technol Int 11:119–126
Cummings DE, Overduin J, Foster-Schubert KE 2004 Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab 89:2608–2615
Brolin RL, Robertson LB, Kenler HA, Cody RP 1994 Weight loss and dietary intake after vertical banded gastroplasty and Roux-en-Y gastric bypass. Ann Surg 220:782–790
Kenler HA, Brolin RE, Cody RP 1990 Changes in eating behavior after horizontal gastroplasty and Roux-en-Y gastric bypass. Am J Clin Nutr 52:87–92
Halmi KA, Mason E, Falk JR, Stunkard A 1981 Appetitive behavior after gastric bypass for obesity. Int J Obes 5:457–464
Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, Purnell JQ 2002 Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 346:1623–1630
Cummings DE, Shannon MH 2003 Roles for ghrelin in the regulation of appetite and body weight. Arch Surg 138:389–396[Free Full Text]
Faraj M, Havel PJ, Phelis S, Blank D, Sniderman AD, Cianflone K 2003 Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 88:1594–1602
Tschop M, Smiley DL, Heiman ML 2000 Ghrelin induces adiposity in rodents. Nature 407:908–913
Tschop M, Wawarta R, Riepl RL, Friedrich S, Bidlingmaier M, Landgraf R, Folwaczny C 2001 Post-prandial decrease of circulating human ghrelin levels. J Endocrinol Invest 24:RC19–RC21
Asakawa A, Inui A, Kaga T, Yuzuriha H, Nagata T, Ueno N, Makino S, Fujimiya M, Niijima A, Fujino MA, Kasuga M 2001 Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology 120:337–345
Shiiya T, Nakazato M, Mizuta M, Date Y, Mondal MS, Tanaka M, Nozoe S, Hosoda H, Kangawa K, Matsukura S 2002 Plasma ghrelin levels in normal and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 87:240–244
Tomasetto C, Karam SM, Ribieras S, Masson R, Lefebvre O, Staub A, Alexander G, Chenard MP, Rio MC 2000 Identification and characterization of a novel gastric peptide hormone: the motilin-related peptide. Gastroenterology 119:395–405
Ariyasu H, Takaya K, Tagami T et al 2001 Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab 86:4753–4758
Fruhbeck G, Diez-Caballero A, Gil MJ, et al 2004 The decrease in plasma ghrelin concentrations following bariatric surgery depends on the functional integrity of the fundus. Obes Surg 14:606–612
Date Y, Murakami N, Toshinai K, et al 2002 The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology 123:1120–1128
Williams DL, Grill HJ, Cummings DE, Kaplan JM 2003 Vagotomy dissociates short- and long-term controls of circulating ghrelin. Endocrinology 144:5184–5187
Kasiske BL, O’Donnell MP, Keane WF 1992 The Zucker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury. Hypertension 19(Suppl 1):I110–I115
Chapman AE, Kiroff G, Game P, Foster B, O’Brien P, Ham J, Maddern GJ 2004 Laparoscopic adjustable gastric banding in the treatment of obesity: a systematic literature review. Surgery 135:326–351
Beck B, Richy S, Stricker-Krongrad A 2003 Ghrelin and body weight regulation in the obese Zucker rat in relation to feeding state and dark/light cycle. Exp Biol Med 228:1124–1131
Date Y, Kojima M, Hosoda H, Sawaguchi A, Mondal MS, Suganuma T, Matsukura S, Kangawa K, Nakazato M 2000 Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 141:4255–4261
Matsumoto M, Hosoda H, Kitajima Y, Morozumi N, Minamitake Y, Tanaka S, Matsuo H, Kojima M, Hayashi Y, Kangawa K 2001 Structure-activity relationship of ghrelin: pharmacological study of ghrelin peptides. Biochem Biophys Res Commun 14;287:142–146.
Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K 1999 Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656–660
Gauna C, Meyler FM, Janssen JA, Delhanty PJ, Abribat T, van Koetsveld P, Hofland LJ, Broglio F, Ghigo E, van der Lely AJ 2004 Administration of acylated ghrelin reduces insulin sensitivity, whereas the combination of acylated plus unacylated ghrelin strongly improves insulin sensitivity. J Clin Endocrinol Metab 89:5035–5042
Ariyasu H, Takaya K, Hosoda H, Iwakura H, Ebihara K, Mori K, Ogawa Y, Hosoda K, Akamizu T, Kojima M, Kangawa K, Nakao K 2002 Delayed short-term secretory regulation of ghrelin in obese animals: evidenced by a specific RIA for the acylated form of ghrelin. Endocrinology 143:3341–3350
English PJ, Ghatei MA, Malik IA, Bloom SR, Wilding JP 2002 Food fails to suppress ghrelin levels in obese humans. J Clin Endocrinol Metab 87:2984
Tschop M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML 2001 Circulating ghrelin levels are decreased in human obesity. Diabetes 50:707–709
Sakata I, Nakamura K, Yamazaki M, Matsubara M, Hayashi Y, Kangawa K, Sakai T 2002 Ghrelin-producing cells exist as two types of cells, closed- and opened-type cells, in the rat gastrointestinal tract. Peptides 23:531–536
Williams DL, Cummings DE, Grill HJ, Kaplan JM 2003 Meal-related ghrelin suppression requires postgastric feedback. Endocrinology 144:2765–2767
Rubino F, Marescaux J 2004 Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg 239:1–11
Buchwald H 2002 A bariatric surgery algorithm. Obes Surg 12:733–746
Rubino F, Gagner M 2002 Potential of surgery for curing type 2 diabetes mellitus. Ann Surg 236:554–559
Pories WJ, Swanson MS, MacDonald KG, Long SB, Morris PG, Brown BM, Barakat HA, deRamon RA, Israel G, Dolezal JM 1995 Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 222:339–350
Fobi MA, Lee H 1994 SILASTIC ring vertical banded gastric bypass for the treatment of obesity: two years of follow-up in 84 patients. J Natl Med Assoc 86:432
Capella JF, Capella RF 2002 An assessment of vertical banded gastroplasty-Roux-en-Y gastric bypass for the treatment of morbid obesity. Am J Surg 183:117–123
Rubino F, Gagner M, Gentileschi P, Kini S, Fukuyama S, Feng J, Diamond E 2004 The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg 240:236–242
MacNormal LD, Rhode BM, Nohr CW 2000 Late outcome of isolated gastric bypass. Ann Surg 231:524–528
Chomczynski P, Sacchi N1987 Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156–159(Francesco Rubino, Philipp)
Address all correspondence and requests for reprints to: Francesco Rubino, M.D., Institut de Recherche Contre les Canceurs de l’Appareil Digestif-European Institute of Telesurgery, 1 Place de l’Hopital, 67091 Strasbourg, France. E-mail: f.rubino@lycos.com.
Abstract
Circulating levels of ghrelin, a stomach peptide that promotes food intake, rise before and fall after meal. We aimed to investigate whether there is an independent contribution of the small bowel to the regulation of ghrelin and appetite. A duodenal-jejunal bypass (DJB) with preservation of normal gastric volume and exposure to nutrients was performed in 12-wk-old obese Zucker ZDF fa/fa rat. Food intake, weight gain, 48-h fasting, and 24-h refeeding levels of total and acylated ghrelin were measured. The DJB was challenged against gastric banding (GB), diet, and a sham operation in matched animals. Normal controls were age-matched Wistar rats, which underwent either DJB or a sham operation. The Zucker obese animals showed a paradoxical increase of acylated ghrelin levels after refeeding (+30% with respect to fasting levels; P = 0.001), an abnormality that was completely reversed only by the DJB (–30%; P = 0.01) but not after GB, diet, or sham operation. In obese rats, the DJB resulted in significantly less food intake and weight gain compared with both GB (P < 0.05) and sham operation (P < 0.01). In sharp contrast, the DJB did not alter food intake and weight gain in normal rats. The DJB does not physically restrict the flow of food but restores meal-induced suppression of acylated ghrelin and significantly reduces food intake in Zucker obese rats. These findings suggest an independent intestinal contribution to the regulation of the dynamic ghrelin response to eating and the possibility that defective signaling from the proximal bowel could be involved in the pathogenesis of obesity/hyperphagia.
Introduction
OBESITY IS CONSIDERED the disease of the 21st century (1). At present, only bariatric surgery achieves major long-term weight loss (2, 3), possibly by counteracting the compensatory mechanisms that usually undermine the efficacy of nonsurgical strategies.
The Roux-en-Y gastric bypass (RYGB), which is one of the most effective and commonly performed procedures (4), includes reduction of gastric capacity to about 5% of its normal volume and a bypass of 95% of the stomach, the entire duodenum, and part of the jejunum (5, 6). In contrast to pure restrictive operations such as the adjustable gastric banding (AGB) and vertical banded gastroplasty, which simply induce early satiety during a meal (7), the RYGB reduces the number of meals and snacks per day and restricts consumption of calorie-dense foods (7, 8, 9, 10). Hence, satiety after RYGB extends well beyond the immediate postprandial period and therefore cannot be explained by gastric restriction alone. Understanding how RYGB prevents compensatory hunger after surgical weight loss may facilitate the development of new antiobesity drugs and perhaps shed light on the pathophysiology of obesity, which still remains elusive.
In 2002, Cummings et al. (11) found remarkably low plasma levels of ghrelin, a circulating orexigen (appetite stimulant), in patients who had undergone weight loss by RYGB, a finding that is in striking contrast with the fact that weight loss induced by dieting, anorexia, or regular physical exercise characteristically results in high levels of circulating ghrelin (11, 12). These authors suggested that ghrelin suppression might explain the loss of hunger after RYGB and possibly contributes to surgically induced weight loss (11). However, the issue is still controversial, as other series reported in the literature showed unchanged or even increased levels of circulating ghrelin in patients undergoing RYGB (13).
Ghrelin is a peptide hormone whose plasma levels increase before meals and decrease after food intake in humans and rodents (14, 15, 16). Because ingested nutrients are dominant regulators of ghrelin production (7, 12, 17) and the majority of ghrelin-producing tissue is located in the proximal stomach (18, 19), it has been hypothesized that RYGB disrupts ghrelin regulation by permanently excluding the fundus from contact with nutrients (7, 11, 20). Accordingly, differences in surgical technique, such as leaving behind a larger gastric pouch and an incomplete exclusion of the fundic part of the stomach from contact with the nutrient load, might explain why RYGB fails to suppress circulating ghrelin levels in some instances (12).
Although this is a plausible hypothesis, it is also entirely possible that changes in circulating ghrelin are the result of signals originating further downstream the gastrointestinal tract, away from the stomach, possibly as the result of the rerouting of food through the bowel according to the RYGB.
To test the hypothesis that intestinal signals are involved in the regulation of ghrelin production, we used a modified RYGB, which leaves the stomach intact and diverts food from the pyloric area directly to the distal jejunum (Fig. 1A). With this duodenal-jejunal bypass (DJB), the entire gastric ghrelin-producing tissue is left in digestive continuity, that is, in contact with nutrients. The operation does not involve any type of vagotomy, which could also influence ghrelin secretion (21, 22). Consequently, any change in circulating ghrelin levels occurring after DJB would be secondary to postgastric signals. Because this model does not impose any mechanical restriction on the flow of food, we also aimed to investigate whether the proximal bowel bypass may per se contribute to the control of appetite and weight loss.
FIG. 1. Surgical operations. A, DJB. The operation excludes the duodenum and jejunum from the flow of food. The length of the bypassed bowel is approximately the same as in standard RYGB in humans, but the DJB does not include bypass or restriction of the stomach. B, The GB operation provides a model of pure gastric restriction by inducing significant mechanical narrowing of the rat’s stomach. A nonresorbable inextensible band was placed just below the gastroesophageal junction calibrated to a standard length to provide a similar degree of gastric restriction in all animals.
Materials and Methods
Animals and chow diet
Male Zucker ZDF fa/fa rats aged 10 wk were purchased from Charles River Laboratories (l’Arbresle, France). Zucker ZDF rats are a widely used animal model of obesity and type 2 diabetes; they are characterized by leptin resistance, insulin resistance, and hyperphagia (22). Normal control animals were age-matched Wistar rats. Both obese animals and normal controls were housed under constant ambient temperature and humidity and in a 12-h light, 12-h dark cycle. All animals had free access to tap water and were ad libitum fed with Purina diet 5008 (IPS LTD, London, UK). The study was approved by the Institutional Animal Care Committee of the Institut de Recherche Contre les Canceurs de l’Appareil Digestif-European Institute of Telesurgery (Strasbourg, France).
Interventions
Zucker ZDF rats underwent one of DJB, GB, and sham operations. Normal controls underwent either DJB or the sham operation. An additional group of age-matched Zucker rats underwent food restriction to provide a model of diet-induced weight loss.
For all surgical procedures, 12-wk-old rats were fasted overnight and anesthetized with 2% isoflurane and air/oxygen.
DJB.
The volume of the stomach was left unperturbed, whereas the entire duodenum and the proximal jejunum were bypassed. This operation is a stomach-sparing bypass that excludes approximately the same amount of foregut excluded in standard RYGB in humans. The length of the bypass was made proportional to human RYGB by measuring the average length of rat intestine, which is approximately 95–100 cm long. The duodenum was separated from the stomach, and the bowel continuity was interrupted at the level of the distal jejunum (10 cm from the ligament of Treitz); the distal of the two limbs was directly connected to the stomach (gastrojejunal anastomosis); the proximal limb carrying the biliopancreatic juices was reconnected downward to the ileum at a distance of 15 cm from the gastrojejunal anastomosis (Roux-en-Y reconstruction). The procedure is illustrated in Fig. 1A.
GB.
The proximal stomach was exposed, and a nonresorbable 4-mm-wide band made of polytetrafluoroethylene (BardPTFE Braided Tape; Bard, Tempe, AZ) was placed just below the gastroesophageal junction, in a similar fashion to that usually performed during AGB in humans (23). The band was calibrated to a standard length to provide a similar degree of gastric restriction in all animals undergoing this operation. In addition, the band was fixed to the gastric wall by several nonresorbable stitches (3/0 nylon) to avoid slippage or band migration. The appropriateness of band position and calibration was checked at the time of death to exclude displacement of the band, which would influence results. Although this annular banding is not adjustable as is the AGB, it provides significant mechanical narrowing of the rat’s stomach, thus imposing restriction on the flow of food. The operation is illustrated in Fig. 1B.
Sham operation.
A gastrotomy was performed at the level of the gastric antrum and closed with an absorbable suture. Furthermore, transections and reanastomosis of the gastrointestinal tract were performed at the level of the duodenum and distal jejunum. The physiological flow of food through the bowel was left intact.
Food intake restriction.
After measuring the mean daily food intake for 2 wk in an age-matched and ad libitum-fed group of rats, access to food was then restricted to only one third of it for 4 consecutive weeks.
Weight change and food intake monitoring
Weight and food intake were measured daily for the duration of the study.
Sampling for plasma hormone measurements
From the tail of conscious rats, blood was collected in EDTA tubes containing the gastrointestinal preservative Aprotinin. After centrifugation at 3000 rpm and 4 C for 12 min, plasma was immediately separated and stored at –80 C until analysis.
Plasma glucose and hormone measurements (Fig. 2)
All blood sampling tests were performed between 0900 and 1100 h.
FIG. 2. Study’s protocol. The figure illustrates the timing of surgeries and testings.
Plasma hormone and glucose levels were measured in both positive and negative energy balance. To induce a negative energy balance, rats were deprived of food but not of water for 48 h before the experiment (48-h fasting). Then, blood samples were obtained again after a 24-h period of refeeding (RF) started at the time the rats had completed the 48-h fasting tests.
Postoperative 48-h fasting and RF tests were performed 3 wk after the operations.
Ghrelin.
Plasma levels of total and acylated ghrelin were determined by two laboratory immunoenzymatic assays using polyclonal rabbit antibodies against the C terminus of rat ghrelin (developed at the Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, France) and N-terminal rat ghrelin (kindly provided by Dr. Hosoda, Osaka, Japan), respectively, and human ghrelin was coupled to acetylcholinesterase (Spibio, Saclay, France) as tracer. The sensitivity was 100 and 20 pg/ml and the intra- and interassay coefficients of variation were 4 and 15%, respectively.
Leptin and insulin.
Plasma leptin and insulin concentrations were determined with RIA kits (Linco Research, St. Charles, MO). The sensitivity was 1 and 0.2 ng/ml, respectively, and the intra- and interassay coefficients of variation were less than 10% (intraassay, 2–4.6 and 1.4–4.6%; interassay, 3–5.7 and 8.5–9.4%, respectively).
Glycemia.
Plasma glucose levels were measured by enzymatic test (glucose oxydase; Beckman analyzer II; Beckman Coulter, Fullerton, CA).
Isolation of RNA and Northern hybridization
A portion of mucosa from the gastric body from each operated rat was taken at the time of and 4 wk after surgery. Surgical biopsies were rapidly frozen in liquid nitrogen. Total RNAs were extracted by the rapid guanidinium isothiocyanate procedure (43). The total RNA was fractionated by electrophoresis on 1% agarose, 2.2 M formaldehyde gels, transferred to nylon membrane (Hybond N; Amersham Corp. Arlington Heights, IL), and immobilized by baking for 2 h at 80 C. RNA loading was visualized by methylene blue staining. Membranes were hybridized at 42 C in 50% formamide, 5x standard saline citrate, 0.4% ficoll, 0.4% polyvinylpyrrolidone, 20 mM sodium phosphate (pH 6.5), 0.5% sodium dodecyl sulfate, 10% dextran sulfate, and 100 μg/ml denatured salmon sperm DNA, for 36–48 h, with the 32P-labeled specific rat ghrelin probe (GenBank accession no. AB029433) diluted to 0.5–1.106 cpm/ml. Stringent washings were performed at 60 C in 0.1x standard saline citrate and 0.1% sodium dodecyl sulfate. Filters were autoradiographed at –80 C for 12–72 h. The effect of different gastric surgeries on the expression level of ghrelin transcripts in the stomach was measured by Northern blot analysis.
Statistical analysis
Results are expressed as mean ± SEM. The changes in food intake, body weight, and plasma ghrelin levels were compared by ANOVA followed by Student’s t test. Comparisons between groups were performed with the unpaired t test. Simple linear regression analysis was used to evaluate correlation between body weight and plasma ghrelin levels. P < 0.05 was considered statistically significant.
Results
Effect of DJB on food intake and weight gain (Table 1)
To investigate the effect of the bypass of the foregut on appetite and body weight regulation, we compared food intake and percentage of weight gain in the different groups of rats for a period of 4 wk after surgery.
TABLE 1. Food intake and weight gain
In obese ZDF rats, the pure mechanical restriction induced by annular GB reduced food intake compared with sham-operated animals (mean daily food intake was 25.1 ± 1.2 vs. 30.8 ± 1.2 g/rat, respectively; P < 0.05; Fig. 3A). However, the most dramatic effect on food intake was seen in DJB-treated obese Zucker rats, which, despite the intact gastric reservoir, showed a lower daily rate of food intake (19.6 + 1.4 g/rat) than both GB and sham animals (P < 0.001) (Fig. 3A). In sharp contrast, DJB did not influence food intake in age-matched Wistar rats as demonstrated by identical average daily rates of food intake between DJB and sham-operated animals during the 4 wk of follow-up (Fig. 3A).
FIG. 3. Food intake and weight gain. A, Effect of DJB on food intake in lean (Wistar) and obese (Zucker) animals. DJB-treated Zucker rats ate significantly less food than GB-treated animals (P < 0.05) and sham-operated controls (P < 0.001). In contrast, DJB did not have any impact on food intake in Wistar rats, as shown by the fact that DJB-treated rats ate the same amount of food per day compared with sham-operated controls. Food intake is expressed as average daily food intake during the 4 wk of follow-up (grams per rat per day). B, Effect of DJB on weight gain in lean (Wistar) and obese (Zucker) animals. In Zucker rats, the DJB resulted in significant less weight gain compared with both GB (P < 0.05) and sham (P < 0.01) operations. In striking contrast, lean animals (Wistar) undergoing DJB showed the same weight gain as sham-operated rats. Weight gain is calculated as the percentage of body weight gained from the day of the operation.
In Zucker rats, the DJB resulted in significantly less weight gain compared with both GB and sham operations (P < 0.01; Fig. 3B). In striking contrast, DJB had no effect on control Wistar rats because they showed the same weight gain after DJB or sham surgery (Fig. 3B).
Zucker rats undergoing marked food restriction achieved a decrease in weight gain that was comparable with that of DJB [6.6 ± 0.6 vs. 5.2 ± 5.3%, respectively; P = not significant (NS)]. Hence, this group of rats was an appropriate control for comparing the hormonal effect of diet-induced weight loss vs. surgically induced weight loss.
Ghrelin mRNA expression
To assess for the integrity of ghrelin-secreting tissue in all rats undergoing surgery, we measured ghrelin mRNA in stomach biopsies obtained at the time of the operation and then again 4 wk after surgery. To ensure that biopsies of gastric mucosa were obtained from the same site at both times, the place of the first biopsy was marked by a stitch of nonresorbable suture.
No change in ghrelin mRNA expression could be detected after any type of surgery in ZDF rats (Fig. 4), demonstrating that all the different gastric surgeries performed in this study preserved the integrity of ghrelin-secreting gastric tissue, without apparent modification of ghrelin gene transcription.
FIG. 4. Expression of ghrelin transcripts by Northern blot analysis of rat’s gastric mucosa. The Northern blot contained approximately 10 μg total RNAs isolated from a nonoperated control rat (lane 1), sham-operated rats (lanes 2 and 3), GB-operated rats (lanes 4 and 5), and DJB-treated rats (lanes 6 and 7). The blot was hybridized using the homologous ppghrelin rat cDNA as a probe. Loading was visualized by the ribosomal 18S staining using methylene blue. RNA sizes are indicated on the left (kilobase pair values).
The effect of energy balance status on circulating ghrelin in obese and normal rats
To investigate ghrelin regulation in normal and obese rats, the effect of negative energy balance (48-h fasting) and positive energy balance (24-h RF) was tested in a group of 12-wk-old nonoperated ZDF rats (16 animals) and in 12-wk-old Wistar rats used as normal controls (16 animals).
Plasma total ghrelin levels were negatively correlated with body weight (r = –0.69, P < 0.001) and were significantly decreased by RF in each type of animals (lean and obese) (Table 2). However, mean ghrelin concentrations per gram of body weight were higher in obese Zucker rats than in normal Wistar rats (10.4 vs. 7.9 pg/ml·g body weight; P < 0.05), consistent with previous reports indicating that the obese Zucker rat is characterized by increased ghrelin mRNA in the stomach and peptide release in the circulation (24).
TABLE 2. Plasma glucose and hormones (nonoperated animals)
Although RF slightly reduced acylated ghrelin levels in normal control Wistar rats, the obese Zucker rats showed a paradoxical increase of acylated ghrelin levels after RF (+30% with respect to fasting levels; P = 0.002; Fig. 5).
FIG. 5. Ghrelin, leptin, insulin, and glycemia. Left, Total ghrelin levels decrease with RF in normal and obese animals. DJB-treated obese ZDF rats showed feeding-induced suppression of acylated ghrelin (–30% with respect to fasting; *, P = 0.01), whereas sham-operated ZDF rats maintained the paradoxical increase of acylated ghrelin with feeding. Right, Zucker ZDF rats are leptin resistant and show higher plasma leptin levels compared with Wistar rat. In Wistar rats, RF significantly increased leptin levels. In Zucker ZDF rats, there were no significant differences in leptin levels between the fasted and fed states; however, unlike sham-operated animals, the DJB-treated rats showed a trend toward increased levels of leptin with RF. Zucker ZDF rats had higher insulin levels than normal Wistar rats in both fasting and fed conditions. DJB-treated ZDF rats had lower levels of insulin compared with sham-operated animals; however, this difference does not reach statistical significance when considering the insulin to body weight ratio. Zucker ZDF rats have type 2 diabetes. Zucker DJB-treated animals had lower plasma glucose levels compared with sham-operated rats, especially in the fed condition. Remarkably, plasma glucose levels of Zucker rats treated by DJB were comparable with those of nondiabetic animals (Wistar rats). W, Wistar; ZDF, Zucker obese diabetic rats; *, P < 0.05; **, P < 0.01; **, P < 0.001.
The effect of surgery on circulating ghrelin levels
To investigate the possible role of the bowel in ghrelin regulation, the effect of DJB on total and acylated ghrelin in both fasted and fed states was compared with that of other gastric surgeries.
The experiments showed that DJB does not suppress circulating ghrelin levels in both normal and obese animals. Indeed, in fasting conditions, the Zucker rats that had undergone the DJB showed higher concentration of total and acylated ghrelin compared with sham-operated controls and GB rats as expected for their lower mean body weight. In normal Wistar animals, DJB did not have any impact on ghrelin response to eating. In contrast, DJB restored feeding-induced suppression of acylated ghrelin in the obese Zucker rats (–30% with respect to fasting; P = 0.01; Fig. 5), whereas neither the GB nor the sham operation caused significant change in the response of acylated ghrelin to food intake in these animals.
To investigate whether the effect of DJB on the ghrelin response to feeding was a specific outcome of the bypass of the proximal bowel and not secondary to the reduction of weight gain induced by the procedure, we tested the effect of diet-induced weight loss on circulating ghrelin in a group of matched Zucker rats undergoing food restriction for 4 wk. Despite a similar degree of weight gain compared with DJB rats, the diet group maintained the paradoxical increase of acylated ghrelin in response to feeding (330 ± 9 vs. 218 ± 23 pg/ml; P < 0.01).
The effect of surgery on leptin and insulin (Table 2 and Fig. 5)
To evaluate the effect of DJB on the secretion of long-term satiety hormones, we measured leptin and insulin levels in fasted and fed condition. Plasma leptin levels were significantly higher in obese Zucker rats compared with normal Wistar animals in both fasted and fed conditions.
The obese Zucker rats who had undergone DJB had significantly lower levels of plasma leptin compared with sham-operated animals and nonoperated controls; however, this difference disappears when considering the ratio of leptin to body weight (0.062 ± 0.003 vs. 0.066 ± 0.003 vs. 0.062 + 0.007 ng/ml·g body weight, respectively; P = NS). Furthermore, there was no difference in leptin levels in these rats after DJB- or diet-induced weight loss, suggesting that there was no direct impact of DJB on leptin secretion.
As expected, ZDF rats had higher plasma insulin levels than normal Wistar animals in both fasting and fed conditions (Fig. 5). Furthermore, in both obese animals and normal controls, RF after 48 h fasting significantly increased plasma insulin levels. DJB-treated ZDF rats had lower levels of insulin compared with sham-operated animals; however, this difference does not reach statistical significance when considering the insulin to body weight ratio.
The effect of DJB on type 2 diabetes
To investigate the effect of DJB on type 2 diabetes in the Zucker ZDF obese diabetic model, we tested plasma glucose in the fasted and fed states. The diabetic rats that had undergone DJB showed plasma glucose levels comparable with nondiabetic controls in both fasted and fed conditions. Sham-operated ZDF animals instead showed significantly higher glycemia, particularly in the fed state (Fig. 5).
Discussion
Ghrelin is a 28-amino-acid residue peptide predominantly produced by enteroendocrine cells in the oxyntic mucosa of the stomach (18, 19, 26). The acylation of one of its serine residues seems to have importance for its endocrine actions (27, 28), but the unacylated form has also been shown to possess metabolic effects (29). In both humans and rodents, ghrelin levels are increased by food deprivation and are decreased postprandially (14, 15, 16). However, how ingested nutrients interact with the ghrelin-producing cells is unclear.
Consistently with previous reports (30), this study found that, in obese Zucker rats, RF is associated with a paradoxical 30% increase of acylated ghrelin levels over fasting concentrations, suggesting that these obese animals are resistant to the meal-induced decrease of circulating acylated ghrelin. English et al. (31) reported that food intake fails to suppress plasma ghrelin levels also in obese humans. This altered endocrine response to eating in obese subjects may contribute to overeating and have implications for antiobesity therapies. Indeed, interventions in the dynamic response of ghrelin to eating, which seems to be altered in rodent and human obese subjects, may be a more effective way to fight obesity.
It has been suggested that RYGB may induce satiety and weight loss through suppression of circulating ghrelin levels (11) and that the mechanism responsible for the effect on ghrelin is the exclusion of the fundus and the isolation of ghrelin-producing cells from direct contact with ingested nutrients (11, 12, 20). However, this explanation is counterintuitive because an empty stomach is usually associated with increased ghrelin levels. We speculated that the rerouting of food through the bowel characteristic of the RYGB may influence ghrelin and appetite independently on fundus exclusion. The rationale for this hypothesis is that ghrelin-secreting cells in the stomach exist in both open and closed types (33), suggesting that they can receive both luminal and neuroendocrine information. Furthermore, recently published experiments put forward the possibility of a postgastric regulation of ghrelin secretion (34).
Unlike the standard RYGB, the DJB that we used in this study is an ideal model to test the hypothesis of an independent intestinal contribution to the regulation of circulating ghrelin levels because it allows one to rule out that any change in ghrelin and/or appetite is related to gastric exclusion/restriction.
Consistent with earlier reports showing no suppression in basal ghrelin levels in humans after RYGB (13), we did not observe suppression of mean total ghrelin levels after DJB. However, in obese Zucker rats, the operation reversed the altered response of circulating acylated ghrelin to feeding. The specificity of this result is demonstrated by the lack of such an effect in GB-treated and sham-operated Zucker rats as well as in the group undergoing diet. These findings support the hypothesis that intestinal signals contribute to the regulation (or dysregulation) of ghrelin secretion. It is possible that DJB influences ghrelin regulation by causing variations in gut hormone peptide YY (PYY) secretion, but other factors may also play a role (i.e. unknown peptides or neural signals from the bowel). Further exploration is necessary to understand how exactly the bowel influences ghrelin regulation.
The effect of DJB on appetite was also noteworthy. In this study, DJB decreased food intake in obese Zucker rats even more than GB, which is a pure restrictive procedure. The theoretical possibility that this effect could be determined by stenosis at the level of the gastrointestinal anastomosis is discounted by the fact that DJB-treated Wistar rats showed the same food intake rates compared with sham-operated controls. Furthermore, obese Zucker rats undergoing DJB still showed the ability to slightly increase their mean daily food intake with growth, a possibility that would be negated by the presence of significant stenosis.
The decreased food intake after the DJB may depend on the increase or enhancement of a factor inducing satiety and/or the reduction or inhibition of an antisatiety signal.
The lack of effect of DJB on food intake in normal Wistar rats, in sharp contrast with what is seen in obese animals, suggests that the second hypothesis is more likely. Previous work from our group showed that DJB does not reduce food intake in Goto-Kakizaki diabetic rats (35), which, like the Wistar rats used in the present study, are nonobese. Altogether, these observations suggest that the DJB may offset an abnormal signal produced by the bowel of hyperphagic/obese animals but not by the intestine of normal and lean rats. This implies the possibility that the gut plays an important role in the pathophysiology of hyperphagia and obesity. We speculate that failure to suppress an orexigenic signal originating in the bowel could result in persistence of the drive to eat even in the setting of positive energy balance, leading to excess energy storage and obesity. Our experiments and the clinical evidence that the most effective surgical operations in maintaining long-term weight loss are those that include a bypass of the foregut (biliopancreatic diversion and RYGB) (36) support the view of obesity as a disease of the bowel.
In this study, the DJB greatly reduced plasma glucose levels in obese diabetic Zucker rats, consistent with the knowledge that RYGB induces remission of type 2 diabetes in the majority of morbidly obese humans (37, 38). A recent study by two of us (F.R. and J.M.) demonstrated that this surgical control of diabetes depends on the bypass of the duodenal-jejunal tract, as shown by the fact that DJB (the same model used in the present study) controls type 2 diabetes in nonobese diabetic rats (Goto-Kakizaki rats), independently of caloric intake and weight loss (35).
Finally, our findings challenge the opinion that RYGB is primarily a restrictive operation (39, 40) and support an endocrine mechanism of action of the procedure (7, 41). Although it is generally believed that the small size of the gastric pouch is essential to reduce caloric intake and guarantee the weight loss effect of RYGB (39, 40, 42), our study suggests that performing an extremely small gastric pouch might be unnecessary. Certainly, a better understanding of the mechanism of action of RYGB is a priority because it may improve the design of bariatric operations.
In summary, our experiments demonstrate that the DJB, an experimental model of proximal bowel bypass with full preservation of the stomach, restores meal-induced suppression of acylated ghrelin and reduces food intake and weight gain in obese Zucker rats. Intriguingly, the operation does not alter food intake in normal Wistar animals. Altogether, these results indicate an intestinal contribution to the regulation of the dynamic ghrelin response to eating and suggest that an abnormal signaling from the proximal bowel may be involved in the pathogenesis of hyperphagia and obesity. Our experimental model, the DJB, may be useful to investigate intestinal factors regulating ghrelin secretion and appetite in the attempt to identify new targets for the development of antiobesity drugs.
Acknowledgments
The authors thank C. Wendling for technical assistance.
References
Kopelman PG 2000 Obesity as a medical problem. Nature 404:635–643
Brolin RE 2002 Bariatric surgery and long-term control of morbid obesity. JAMA 288:2793–2796
Mun EC, Blackburn GL, Matthews JB 2001 Current status of medical and surgical therapy for obesity. Gastroenterology 120:669–681
NIH Consensus Development Panel 1991 Gastrointestinal surgery for severe obesity. Ann Intern Med 115:956–961
Schauer PR, Ikramuddin S 2001 Laparoscopic surgery for morbid obesity. Surg Clin North Am 81:1145–1179
Jacob BP, Gagner M 2003 New developments in gastric bypass procedures and physiological mechanisms. Surg Technol Int 11:119–126
Cummings DE, Overduin J, Foster-Schubert KE 2004 Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab 89:2608–2615
Brolin RL, Robertson LB, Kenler HA, Cody RP 1994 Weight loss and dietary intake after vertical banded gastroplasty and Roux-en-Y gastric bypass. Ann Surg 220:782–790
Kenler HA, Brolin RE, Cody RP 1990 Changes in eating behavior after horizontal gastroplasty and Roux-en-Y gastric bypass. Am J Clin Nutr 52:87–92
Halmi KA, Mason E, Falk JR, Stunkard A 1981 Appetitive behavior after gastric bypass for obesity. Int J Obes 5:457–464
Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, Purnell JQ 2002 Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 346:1623–1630
Cummings DE, Shannon MH 2003 Roles for ghrelin in the regulation of appetite and body weight. Arch Surg 138:389–396[Free Full Text]
Faraj M, Havel PJ, Phelis S, Blank D, Sniderman AD, Cianflone K 2003 Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 88:1594–1602
Tschop M, Smiley DL, Heiman ML 2000 Ghrelin induces adiposity in rodents. Nature 407:908–913
Tschop M, Wawarta R, Riepl RL, Friedrich S, Bidlingmaier M, Landgraf R, Folwaczny C 2001 Post-prandial decrease of circulating human ghrelin levels. J Endocrinol Invest 24:RC19–RC21
Asakawa A, Inui A, Kaga T, Yuzuriha H, Nagata T, Ueno N, Makino S, Fujimiya M, Niijima A, Fujino MA, Kasuga M 2001 Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology 120:337–345
Shiiya T, Nakazato M, Mizuta M, Date Y, Mondal MS, Tanaka M, Nozoe S, Hosoda H, Kangawa K, Matsukura S 2002 Plasma ghrelin levels in normal and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 87:240–244
Tomasetto C, Karam SM, Ribieras S, Masson R, Lefebvre O, Staub A, Alexander G, Chenard MP, Rio MC 2000 Identification and characterization of a novel gastric peptide hormone: the motilin-related peptide. Gastroenterology 119:395–405
Ariyasu H, Takaya K, Tagami T et al 2001 Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab 86:4753–4758
Fruhbeck G, Diez-Caballero A, Gil MJ, et al 2004 The decrease in plasma ghrelin concentrations following bariatric surgery depends on the functional integrity of the fundus. Obes Surg 14:606–612
Date Y, Murakami N, Toshinai K, et al 2002 The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology 123:1120–1128
Williams DL, Grill HJ, Cummings DE, Kaplan JM 2003 Vagotomy dissociates short- and long-term controls of circulating ghrelin. Endocrinology 144:5184–5187
Kasiske BL, O’Donnell MP, Keane WF 1992 The Zucker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury. Hypertension 19(Suppl 1):I110–I115
Chapman AE, Kiroff G, Game P, Foster B, O’Brien P, Ham J, Maddern GJ 2004 Laparoscopic adjustable gastric banding in the treatment of obesity: a systematic literature review. Surgery 135:326–351
Beck B, Richy S, Stricker-Krongrad A 2003 Ghrelin and body weight regulation in the obese Zucker rat in relation to feeding state and dark/light cycle. Exp Biol Med 228:1124–1131
Date Y, Kojima M, Hosoda H, Sawaguchi A, Mondal MS, Suganuma T, Matsukura S, Kangawa K, Nakazato M 2000 Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 141:4255–4261
Matsumoto M, Hosoda H, Kitajima Y, Morozumi N, Minamitake Y, Tanaka S, Matsuo H, Kojima M, Hayashi Y, Kangawa K 2001 Structure-activity relationship of ghrelin: pharmacological study of ghrelin peptides. Biochem Biophys Res Commun 14;287:142–146.
Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K 1999 Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656–660
Gauna C, Meyler FM, Janssen JA, Delhanty PJ, Abribat T, van Koetsveld P, Hofland LJ, Broglio F, Ghigo E, van der Lely AJ 2004 Administration of acylated ghrelin reduces insulin sensitivity, whereas the combination of acylated plus unacylated ghrelin strongly improves insulin sensitivity. J Clin Endocrinol Metab 89:5035–5042
Ariyasu H, Takaya K, Hosoda H, Iwakura H, Ebihara K, Mori K, Ogawa Y, Hosoda K, Akamizu T, Kojima M, Kangawa K, Nakao K 2002 Delayed short-term secretory regulation of ghrelin in obese animals: evidenced by a specific RIA for the acylated form of ghrelin. Endocrinology 143:3341–3350
English PJ, Ghatei MA, Malik IA, Bloom SR, Wilding JP 2002 Food fails to suppress ghrelin levels in obese humans. J Clin Endocrinol Metab 87:2984
Tschop M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML 2001 Circulating ghrelin levels are decreased in human obesity. Diabetes 50:707–709
Sakata I, Nakamura K, Yamazaki M, Matsubara M, Hayashi Y, Kangawa K, Sakai T 2002 Ghrelin-producing cells exist as two types of cells, closed- and opened-type cells, in the rat gastrointestinal tract. Peptides 23:531–536
Williams DL, Cummings DE, Grill HJ, Kaplan JM 2003 Meal-related ghrelin suppression requires postgastric feedback. Endocrinology 144:2765–2767
Rubino F, Marescaux J 2004 Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg 239:1–11
Buchwald H 2002 A bariatric surgery algorithm. Obes Surg 12:733–746
Rubino F, Gagner M 2002 Potential of surgery for curing type 2 diabetes mellitus. Ann Surg 236:554–559
Pories WJ, Swanson MS, MacDonald KG, Long SB, Morris PG, Brown BM, Barakat HA, deRamon RA, Israel G, Dolezal JM 1995 Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 222:339–350
Fobi MA, Lee H 1994 SILASTIC ring vertical banded gastric bypass for the treatment of obesity: two years of follow-up in 84 patients. J Natl Med Assoc 86:432
Capella JF, Capella RF 2002 An assessment of vertical banded gastroplasty-Roux-en-Y gastric bypass for the treatment of morbid obesity. Am J Surg 183:117–123
Rubino F, Gagner M, Gentileschi P, Kini S, Fukuyama S, Feng J, Diamond E 2004 The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg 240:236–242
MacNormal LD, Rhode BM, Nohr CW 2000 Late outcome of isolated gastric bypass. Ann Surg 231:524–528
Chomczynski P, Sacchi N1987 Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156–159(Francesco Rubino, Philipp)